Riluzole Revealed: Could This ALS Drug Provide Hope for MDD?
Riluzole Revealed: Could This ALS Drug Provide Hope for MDD?

In this article
Riluzole Mechanism of Action
In recent years Ketamine has caught a lot of attention as an effective and fast-acting treatment for depression and anxiety. It has sparked a lot of interest in other medications that have similar actions. Riluzole is one of those medications. Riluzole is sold under the brand names Exservan, Rilutek, and Tiglutik. Riluzole is classified therapeutically as a neuroprotectant. It is classified pharmacologically as benzothiazole. Riluzole has several mechanisms of action, one of which is lowering the release of glutamate and blocking the NMDA receptor. This allows Riluzole to lower the actions of glutamate. Overstimulation of glutamatergic neurons has related to increased levels of depression and anxiety. Ketamine is theorized to work in the same way to pronounced effect.
Riluzole Uses
Riluzole has typically been used to treat ALS. It is said to have neuroprotective effects by preventing the excitotoxicity in the glutamatergic neurons. One of the benefits of Riluzole over that of ketamine is that it does not have psychomimetic or hallucinatory effects. It has a vastly better side effect profile than that of ketamine use. It also holds some other advantages over Ketamine such as it can be taken orally and does not require an IV. Ketamine also must be administered in clinics to monitor the IV and potential hallucinatory effects.
Half-life and side effects:
Riluzole has a half-life of 12 hours. Side effects of Riluzole include dizziness, insomnia, fast heart rate, dry mouth, nausea, abdominal pain, joint pain, eczema, and others. Riluzole is well tolerated and does not have any black box warnings like many other medications used to treat depression and anxiety.
Evidence using Riluzole for Anxiety and Depression
There have been quite a few quality studies that have shown evidence in favor of using Riluzole off label for the treatment of anxiety and depression and other psychiatric disorders.
One study states: “several open-label trials have suggested that riluzole, either as monotherapy or as augmentation of standard therapy, reduces symptoms of obsessive-compulsive disorder, unipolar and bipolar depression, and generalized anxiety disorder. In studies of psychiatrically ill patients conducted to date, the drug has been quite well tolerated; common adverse effects include nausea and sedation.” https://pubmed.ncbi.nlm.nih.gov/18698875/
Another one concludes: “In this open-label pilot study, riluzole at a fixed dose of 100 mg/day was associated with rapid and sustained anxiolytic effects in patients with generalized anxiety disorder, with favorable tolerability.” https://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.162.12.2379
One other says: “This study supports the utility of riluzole as a prophylactic medication for preventing anhedonia, anxiety, and helplessness symptoms associated with stress-related disorders.” https://www.biorxiv.org/content/10.1101/2020.08.07.242057v3.full
There are also several other studies that claim Riluzole’s use in this manner could be beneficial for those suffering from treatment resistant anxiety and depression. They will be linked at the end of this article. The evidence for Riluzole’s use is there. It has not caught on with psychiatrists yet because it is a new medication for ALS, and its use in psychiatric disorders has not been well-established yet.
Why Riluzole Might Be a good Option for You.
Riluzole is unique in its mechanism of action. It is similar but different from Ketamine. It has convincing evidence behind its use. If you are someone who has already failed medication trials with first- and second-line treatments for anxiety and depression, Riluzole may be something you want to look at. Your psychiatrist may be hesitant to prescribe this medication at first. Showing them some of this evidence may help convince them it is an effective use of your time.
The Anxious Resistance Take on Riluzole
Out of all the investigational antidepressants that we report on, Riluzole shows some of the most promise. It is well tolerated. It has robust evidence behind its use as an anxiolytic and an antidepressant. It is already on the market. The biggest thing left is for there to be more personal, anecdotal evidence for its use. That means that it needs to catch on with prescribers and be used more often. This medication shows a lot of potential.
Other Sources of Evidence:
“Riluzole's side effect profile is favorable and preliminary results regarding riluzole for the treatment of severe mood, anxiety and impulsive disorders are encouraging.”
https://link.springer.com/article/10.2165/00023210-200822090-00004
“Conclusions: These data suggest that riluzole augmentation produces antidepressant and anxiolytic effects in patients with treatment-resistant depression.”
https://pubmed.ncbi.nlm.nih.gov/17141740/
Words worth knowing
Insomnia
A sleep disorder involving persistent difficulty falling asleep, staying asleep, or getting restorative sleep.
Black box warning
The FDA’s most prominent medication warning, used when a medicine carries a serious or potentially life-threatening risk.
